307 related articles for article (PubMed ID: 30940109)
21. MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma.
Zhuang L; Shou T; Li K; Gao CL; Duan LC; Fang LZ; Zhang QY; Chen ZN; Zhang C; Yang ST; Li GF
J Cell Mol Med; 2017 Nov; 21(11):2852-2862. PubMed ID: 28653805
[TBL] [Abstract][Full Text] [Related]
22. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
Ferrer I; Quintanal-Villalonga Á; Molina-Pinelo S; Garcia-Heredia JM; Perez M; Suárez R; Ponce-Aix S; Paz-Ares L; Carnero A
J Exp Clin Cancer Res; 2018 Aug; 37(1):195. PubMed ID: 30119639
[TBL] [Abstract][Full Text] [Related]
23. Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human Ovarian Cancer Cell Invasion In Vitro.
Meng F; Chen X; Song H; Lou G; Fu S
Chem Biol Drug Des; 2016 Jan; 87(1):121-30. PubMed ID: 26247403
[TBL] [Abstract][Full Text] [Related]
24. Reduced CENPU expression inhibits lung adenocarcinoma cell proliferation and migration through PI3K/AKT signaling.
Li J; Wang ZG; Pang LB; Zhang RH; Wang YY
Biosci Biotechnol Biochem; 2019 Jun; 83(6):1077-1084. PubMed ID: 30849291
[TBL] [Abstract][Full Text] [Related]
25. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
26. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
27. Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
Kinehara Y; Nagatomo I; Koyama S; Ito D; Nojima S; Kurebayashi R; Nakanishi Y; Suga Y; Nishijima-Futami Y; Osa A; Nakatani T; Kato Y; Nishide M; Hayama Y; Higashiguchi M; Morimura O; Miyake K; Kang S; Minami T; Hirata H; Iwahori K; Takimoto T; Takamatsu H; Takeda Y; Hosen N; Hoshino S; Shintani Y; Okumura M; Kumagai T; Nishino K; Imamura F; Nakatsuka SI; Kijima T; Kida H; Kumanogoh A
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568033
[TBL] [Abstract][Full Text] [Related]
28. Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers.
Cheng X; Tian X; Wu X; Xing X; Du H; Zhou C; Zhang Q; Hao C; Wen X; Ji J
PLoS One; 2016; 11(7):e0158715. PubMed ID: 27391361
[TBL] [Abstract][Full Text] [Related]
29. Serum α-1 Acid Glycoprotein is a Biomarker for the Prediction of Targeted Therapy Resistance in Advanced EGFR-positive Lung Adenocarcinoma.
Xu YF; Xu Y; Li X; Yang XM
Comb Chem High Throughput Screen; 2018; 21(10):755-759. PubMed ID: 30663564
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.
Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M
Med Oncol; 2014 Jun; 31(6):974. PubMed ID: 24816841
[TBL] [Abstract][Full Text] [Related]
33. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
[TBL] [Abstract][Full Text] [Related]
34. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
35. Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma.
Roy G; Roy P; Bhattacharjee A; Shahid M; Misbah M; Gupta S; Husain M
Int J Biol Markers; 2018 Aug; 33(3):283-292. PubMed ID: 29882487
[TBL] [Abstract][Full Text] [Related]
36. Keratin 17 Promotes Lung Adenocarcinoma Progression by Enhancing Cell Proliferation and Invasion.
Liu J; Liu L; Cao L; Wen Q
Med Sci Monit; 2018 Jul; 24():4782-4790. PubMed ID: 29991674
[TBL] [Abstract][Full Text] [Related]
37. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
[TBL] [Abstract][Full Text] [Related]
38. BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion.
Shen C; Wang Y; Wei P; Du X
BMC Cancer; 2016 Aug; 16(1):670. PubMed ID: 27553041
[TBL] [Abstract][Full Text] [Related]
39. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
40. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling.
Li L; Wei XH; Pan YP; Li HC; Yang H; He QH; Pang Y; Shan Y; Xiong FX; Shao GZ; Zhou RL
Oncogene; 2010 Oct; 29(43):5785-95. PubMed ID: 20711237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
